When does Stelara (ustekinumab) lose exclusivity in Europe in 2024–2025?
The information provided doesn’t include Stelara’s European patent or regulatory exclusivity expiry dates for 2024 or 2025, so an exact “loss of exclusivity” timeline for Europe cannot be confirmed from the available material.
What “loss of exclusivity” can mean for Stelara in Europe
In Europe, when people say a drug is about to “lose exclusivity,” they often mean one or more of the following:
- Patent expiry (including specific patents that protect the product or indications).
- Supplementary Protection Certificate (SPC) expiry, which can extend patent life for medicines.
- Regulatory data exclusivity / market exclusivity under EU rules (these are separate from patent/SPC terms).
Without the specific legal and regulatory documents (or the source you’re using), the exact trigger for “loss of exclusivity” in 2024–2025 can’t be pinned down.
Will biosimilars launch immediately after exclusivity ends?
Even after exclusivity ends, biosimilar launch timing depends on factors like:
- Whether a competing biosimilar has regulatory approval first (and for which indication/dose).
- Patent/SPC status of individual claims (different patents can still block entry even if some have expired).
- Any litigation and negotiated settlement outcomes.
So the first EU sales of a biosimilar may occur later than the date exclusivity ends, depending on the patent landscape.
How to get the exact Europe 2024/2025 date you’re looking for
To give a precise answer, I need one of the following:
- The country scope you mean by “Europe” (EU5 vs UK, etc.) and whether you care about end of SPC vs end of data/market exclusivity.
- The listing/source you’re using (often it’s an EMA/P&I summary, UK PPRS, national health authority pipeline, or a specific patent register entry).
- Any reference you already have (e.g., a link or document name), so I can align the dates to the exact exclusivity definition.
If you share the jurisdiction (EU vs UK) and whether you mean patent/SPC or regulatory exclusivity, I can narrow the 2024–2025 “loss of exclusivity” window to the correct trigger.
Sources
No sources were provided with your question.